This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Dalbavancin Study Results To Be Presented In Three Posters At The 53rd Annual ICAAC Meeting

CHICAGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two Phase 3 clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, September 10-13, 2013. The trials were conducted via a Special Protocol Assessment based on the FDA's Draft Guidance for Developing Drugs for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Dalbavancin is under investigation for the treatment of ABSSSI caused by susceptible Gram-positive microorganisms. These data will be used to support the company's anticipated submission of a New Drug Application to the U.S. Food and Drug Administration at the end of September 2013.

In addition, R.M. Alden Research Lab will present in vitro data regarding the activity of dalbavancin against isolates obtained from osteomyelitis infections. This research was supported by a grant from Durata Therapeutics.

The following posters will be presented:

Tuesday, September 10, 2013
12 p.m. - 2 p.m.
Title: DISCOVER 1: A Randomized, Double-blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: H. W. Boucher 1, M. Wilcox 2, G. H. Talbot 3, A. Das 4, S. Puttagunta 5, M. Dunne 5 ( 1Tufts Med. Ctr., Boston, MA,  2Leeds Teaching Hosp., Leeds, UNITED KINGDOM,  3Talbot Advisors, LLC, Anna Maria, FL,  4InClin, San Mateo, CA,  5Durata Therapeutics, Branford, CT)
Poster #: L-201
 
Tuesday, September 10, 2013 
12 p.m. – 2 p.m.
Title: DISCOVER 2: A Randomized, Double-Blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: M. Wilcox 1, H. W. Boucher 2, G. H. Talbot 3, A. F. Das 4, S. Puttagunta 5, M. Dunne 5 ( 1Leeds Teaching Hosp., Leeds, UNITED KINGDOM,  2Tufts Med. Ctr., Boston, MA,  3Talbot Advisors, LLC, Anna Maria, FL,  4InClin, San Mateo, CA,  5Durata Therapeutics, Branford, CT)
Poster #: L-202
 
Tuesday, September 10, 2013 
12 p.m. – 2 p.m.
Title: In Vitro Activity of Dalbavancin Against Consecutive Isolates of Staphylococcus Species Recovered from Osteomyelitis Infections
Authors: D. M. Citron, E. J. Goldstein (R.M. Alden Res. Lab., Culver City, CA)
Poster #: E-140

The abstracts are currently available on the ICAAC website at www.icaac.org and copies of the posters will be available following the ICAAC meeting at www.duratatherapeutics.com

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. 

Stock quotes in this article: DRTX 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs